FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2272-2273 December 4, 2003 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Grossman, H. B. PubMed Citation

To the Editor: On the basis of their findings in a well-designed, randomized trial involving patients with muscle-invasive bladder cancer, Grossman et al. (Aug. 28 issue)¹ conclude that neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC), followed by radical cystectomy, improved survival, as compared with cystectomy alone. We want to point out some important considerations about the treatment received by patients in the control group (those treated with cystectomy alone).

First, 19 percent of patients in the cystectomy-alone group (30 of 154) did not undergo cystectomy according to the protocol, and no additional information about the alternative treatments given . . . [Full Text of this Article]

This article has been cited by other articles:

• Theodore, C., Bidault, F., Bouvet-Forteau, N., Abdelatif, M., Fizazi, K., di Palma, M., Wibault, P., de Crevoisier, R., Laplanche, A. (2006). A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 17: 990-994 [Abstract] [Full Text]